SecBot SecBot
PRESS-RELEASE ·Filed May 5, 2026

CYTK

Cytokinetics, Incorporated
BULLISH
Impact 8/10
Horizondays Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

This is a transformative readout for CYTK, the first positive Phase 3 trial in nHCM with no approved therapies. Expect significant upside at open. Key catalysts ahead: FDA submission timing (likely H2 2026), pricing/reimbursement for expanded indication, and potential partnership or M&A interest given the now de-risked pipeline. Monitor the investor call on May 5 at 8:00 AM ET for regulatory timeline details.

DirectionBullish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$77.09
T+0 close · May 5, 2026 · via day close
Latest settled
+4.32%
T+60 · $80.42
Vs SPY
+1.58%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 5 $77.09entry
  2. T+1 · 7mo ago −2.92%α −4.30% · $74.84
  3. T+5 · 6mo ago −2.96%α −4.94% · $74.81
  4. T+20 · 6mo ago −8.02%α −12.97% · $70.91
  5. T+60 · 4mo ago +4.32%α +1.58% · $80.42

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cytokinetics announced positive topline results from the ACACIA-HCM Phase 3 trial of aficamten in non-obstructive HCM, meeting both dual primary endpoints with statistically significant improvements in KCCQ-CSS (p=0.021) and pVO2 (p=0.003) vs placebo at Week 36. This is a major catalyst as there are currently no approved therapies for nHCM, potentially expanding aficamten's addressable market by ~50% (half of all HCM patients).

Key Facts

  • ACACIA-HCM met dual primary endpoints: KCCQ-CSS improvement of 3.0 points (p=0.021) and pVO2 improvement of 0.67 mL/kg/min (p=0.003) vs placebo at Week 36
  • Statistically significant improvements (p<0.001) in key secondary endpoints: NYHA class, composite z-score of VE/VCO2 and pVO2, and NT-proBNP
  • No new safety signals; LVEF <50% occurred in 10% of aficamten vs 1% placebo patients, with 2 serious heart failure adverse events in aficamten arm
  • Aficamten (MYQORZO) already approved in U.S., EU, and China for obstructive HCM; this trial targets the ~50% of HCM patients with non-obstructive disease who have no approved therapies
  • Company plans to discuss results with FDA and other regulatory authorities for potential label expansion

Financial Impact

Potential to double aficamten's addressable patient population from ~150,000 diagnosed oHCM patients to ~300,000 diagnosed HCM patients in the U.S., with an estimated 400,000-800,000 undiagnosed patients

revenuemarket share

Risk Factors

  • Safety signal: 10% LVEF <50% and 2 serious heart failure events on aficamten may prompt FDA scrutiny despite no new safety signals
  • Regulatory risk: FDA could require additional data or limit label to specific nHCM subpopulations
  • Competition: Bristol Myers Squibb's mavacamten (Camzyos) is approved for oHCM but not nHCM; could potentially pursue nHCM indication
  • Commercial execution risk: Expanding from oHCM to nHCM requires new physician education and patient identification

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3287549

Track record

46 reports on CYTK

Performance horizon

7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $56.13 +4.41% settles Dec 15
  2. Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $56.13 +0.00% settles Dec 14
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $56.13 −0.09% settles Dec 9
  4. Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $56.13 −0.09% settles Dec 9
  5. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $56.13 +1.80% settles Dec 8
  6. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $56.13 +1.80% settles Dec 8
  7. Nov 4, 202612d ago 8-K Bullish 6/10 No price data
  8. Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $56.13 +1.04% settles Dec 4
  9. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $56.13 −11.75% settles Dec 3
  10. Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $56.13 −9.51% settles Dec 1
Showing 10 of 46

US Market Status

Market Closed · Opens Wed (12h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026